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Abstract: Primary graft dysfunction (PGD) following lung trans-
plantation is clinically similar to the acute respiratory distress syndrome.
Because alcohol abuse independently increases the incidence of acute
respiratory distress syndrome in at-risk individuals, we hypothesized
that donor alcohol use is correlated with an increased risk of PGD. As
a pilot study, we collected alcohol use histories using a validated
instrument, the Alcohol Use Disorder Identiﬁcation Test questionnaire,
from 74 donors and correlated these with the development of PGD in
corresponding recipients. Nineteen percent (14/74) of donors were
classiﬁed as heavy alcohol users, as deﬁned by the Alcohol Use
Disorder Identiﬁcation Test scores $8. In the 1st 4 days post-
transplantation, similar percentages of recipients developed grade 3
PGD on at least 1 day (heavy alcohol user 5 29% [4/14] versus lighter
alcohol user5 27% [16/60]); however, recipients receiving a lung from
a heavy alcohol user were more likely to have multiple and consecutive
days of grade 3 PGD, especially in the 1st 48 hours post-transplant.
Both median length of stay in the intensive care unit and hospital were
somewhat longer in the heavy alcohol user group (9 versus 7 days and
19.5 versus 17.5 days, respectively). If these preliminary ﬁndings are
validated in a multi-center study, they would have important implica-
tions not only for our understanding of the pathophysiology of PGD but
also for the development of novel treatments based on the evolving
evidence from experimental and clinical studies on how alcohol abuse
renders the lung susceptible to acute edematous injury.
Key Indexing Terms: Primary graft dysfunction; Lung transplantation;
Lung donor; Recipient; AUDIT; Alcohol use. [Am J Med Sci 2015;349
(2):117–123.]
P rimary graft dysfunction (PGD) is the leading cause of deathin the immediate period following lung transplantation and
has an incidence of 15% to 25%.1 Unfortunately, there are no
effective therapies, and even with supportive care, the mortality
can be as high as 43%.2,3 It had previously been assumed that
the factors predisposing to PGD pertain to the surgical proce-
dure or to the allograft recipient.4 However, compelling exper-
imental and clinical evidence suggests that donor-related risks
factors are also important in the development of PGD. For exam-
ple, it is now recognized that donor characteristics, such as age,
smoking and mismatches with the donor in sex or race, contrib-
ute to poor recipient outcomes.4 We recently demonstrated
a potential association between elevated donor levels of receptor
for advanced glycation end-products and the development of
PGD.5 In addition, other studies have shown that donor bio-
markers such as interleukin (IL)-8,6 vascular endothelial growth
factor7 and certain gene expression proﬁles8 are associated with
an increased risk of developing PGD. Importantly, because there
are no proven medical treatments for PGD, identiﬁcation of
additional biomarkers to accurately identify allografts that are
at higher risk for developing this serious condition are needed.9
The features of PGD represent essentially a form fruste
of the acute respiratory distress syndrome (ARDS), the most
severe form of acute lung injury (ALI), which occurs within the
unique context of lung transplantation.10 In the past 15 years,
a strong independent association between alcohol abuse and
ARDS has been identiﬁed, and our group at Emory University
has been at the forefront of investigating the mechanisms by
which alcohol abuse renders the lung susceptible to acute edem-
atous injury. Speciﬁcally, alcohol abuse independently and sig-
niﬁcantly increases the risk of ARDS 2- to 4-fold in critically ill
individuals.11,12 Although the mechanisms underlying this asso-
ciation are still being investigated, we have clear evidence from
experimental models and clinical studies that chronic alcohol
ingestion causes oxidative stress and depletes the pool of the
antioxidant glutathione within the alveolar space.13,14 Alcohol-
induced oxidative stress causes previously unrecognized alve-
olar epithelial dysfunction, including increased paracellular
permeability, decreased liquid clearance, impaired surfactant
production and decreased cell viability.13,15–17
This “alcoholic lung” phenotype is clinically silent in
that the physiological perturbations identiﬁed in both experi-
mental models and in otherwise healthy alcoholic individuals
are not readily detectable without sophisticated measurements
and do not manifest as signiﬁcant lung dysfunction until an
acute inﬂammatory stress, such as sepsis or aspiration, unmasks
them. Speciﬁcally, alcohol abuse alone does not cause lung
injury but rather it signiﬁcantly lowers the threshold for its
development. This previously unrecognized association
between alcohol abuse and ARDS/ALI was identiﬁed only
when prospective studies were done using accurate alcohol
use assessments such as the Alcohol Use Disorder Identiﬁcation
Test (AUDIT).12 However, this type of prospective investiga-
tion has not heretofore been applied in the unique context of
lung transplantation and PGD. Therefore, we sought to deter-
mine if donor alcohol abuse likewise increased the risk of PGD.
As a 1st step and a means of identifying biological plausibility,
we demonstrated that chronic alcohol use by the donor exacer-
bated airway injury in allograft recipients using an experimental
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rat model of heterotopic tracheal transplantation.18 We then
initiated a single-center pilot study within our Emory Alcohol
and Lung Biology Center, in collaboration with the McKelvey
Center for Lung Transplantation at Emory University, to collect
preliminary data in support of such an association that could
stimulate the design and implementation of a larger multi-center
study. Such information would have enormous implications for
both the selection of lung allograft donors and for the develop-
ment of novel therapeutic approaches to mitigate the devastat-
ing consequences of PGD.
We reasoned that this study was important to the lung
transplant community, which includes donors, recipients and the
tens of thousands of healthcare professionals involved in lung
transplantation. Unfortunately, despite advances in lung trans-
plantation techniques and identiﬁcation of appropriate selection
criteria, our ability to predict which lung allograft recipients will
develop PGD is at present imprecise,19 and our limited under-
standing of the fundamental mechanisms driving the development
of PGD has frustrated our attempts to identify effective therapies
beyond supportive care. In light of recent experimental and clin-
ical evidence revealing the strong and independent association
between alcohol abuse and ALI, we felt that there were compel-
ling reasons to examine whether donor alcohol abuse increased
the risk of PGD. To address this hypothesis, we initiated a pilot
study at Emory University through our Alcohol and Lung
Biology Center to study the relationship between donor alcohol
use and the development of PGD in lung transplant recipients.
PATIENTS AND METHODS
Donor and Recipient Characteristics
Eligibility
Between February 2007 and January 2009 at Emory
Hospital in Atlanta, GA, 88 consecutive lung transplant
recipients and their lung donors were considered for eligibility.
Exclusion criteria included being re-transplanted (n 5 4), no
consent (n 5 2) and improper lung preparation (n 5 3). Two
subjects received a lung from the same donor; 1 subject was
randomly selected for inclusion in the analysis. Therefore, in
total, there were 78 eligible lung allograft recipients, of whom
74 had their donor’s alcohol use quantiﬁed using the AUDIT.
All analyses are based on these 74 recipients.
Donor Lung Criteria
Lung donors were recruited from brain-dead patients
consented for lung donation. Donor lungs used for trans-
plantation at our institution had to meet the following inclusion
criteria at the time of organ recovery: (1) compatible ABO
blood group, (2) PaO2/FiO2 . 300 mm Hg, (3) chest radio-
graph without focal or signiﬁcant ﬁndings consistent with pneu-
monia or lung contusion and (4) adequate bronchoscopic
assessment was performed to ensure that no obvious aspiration
was present. Explanted lungs were preserved using Perfadex
(Vitrolife, Gothenburg, Sweden). The allograft ischemia time
was recorded for all lung transplants.
Lung Recipients Criteria
Recipients listed at our institution received transplants
according to their clinical priorities. Clinical data were available
for all lung transplant recipients. This study was approved by
the institutional review board at Emory University.
Immunosuppressive Therapy
All recipients received a standard immunosuppression
protocol following transplantation, consisting of induction with
IL-2 receptor antagonist and maintenance with a 3-drug
combination with the calcineurin inhibitor tacrolimus, azathio-
prine and steroids as described previously.20
Transplant Infection Prophylaxis
All recipients received antibiotics up to 5 days after
surgery, and subsequent antibiotic therapy length was deter-
mined based on ﬁnal donor culture and intra-operative bron-
chial cultures obtained by swab at the time of surgery. All
recipients received prophylaxis after transplantation against
cytomegalovirus, Pneumocystis jirovecii and Aspergillus spp.
as previously described.21
PGD Treatment
PGD treatment involved administration of diuretics,
prolonged mechanical ventilation with adjusted FiO2 and pos-
itive end-expiratory pressure and inhaled NO as required.
Predictor and Outcomes Definitions
Deﬁnition of Alcohol Abuse
The AUDIT is a 10-question questionnaire that queries
recent alcohol use, alcohol dependence symptoms and alcohol-
related problems and has a sensitivity .90% to distinguish
hazardous and harmful alcohol use whether the information is
self-reported or obtained from a surrogate add.22,23 Respondents
with scores $8 are categorized as heavy alcohol users, and
those with scores ,8 are categorized as light alcohol users.
Scoring of PGD
PGD was scored from 0 to 3 using chest radiographs and
PaO2/FiO2 ratios per the guidelines of the International Society
for Heart and Lung Transplantation. Scores were assigned at
regular and/or speciﬁed intervals during the 1st 96 hours after
lung transplantation.24 Before removal of their endotracheal
tube, all recipients received a bronchoscopy to assess bronchial
anastomosis and bronchoalveolar lavage ﬂuid was obtained and
submitted for culture. Furthermore, for recipients ﬁtting clinical
criteria of PGD, trans-bronchial biopsies were performed to rule
out additional potential causes for abnormal radiographs/poor
oxygenation.
Covariates Examined
Potential confounding variables were examined that
could inﬂuence any observed association between donor
alcohol abuse and subsequent PGD. These included:
Donor variables: Age, sex, race, smoking history (.1 pack-
year) and cause of death.
Recipient variables: Age, race, sex and underlying lung disease,
length of stay (LOS) in the intensive care unit (ICU) and
overall hospital LOS.
Surgical variables: Transplant procedure, utilization of pulmo-
nary cardiopulmonary bypass, ischemia time and dura-
tion of mechanical ventilation
LOS: LOS in the ICU and the overall hospital LOS.
Statistics
As this was a single-center pilot study with a limited
number of participants, we recognized that it was unlikely that
we would be able to identify a statistically signiﬁcant difference
in the incidence of PGD in allograft from donors with or
without alcohol abuse unless that difference was very large.
Therefore, the primary goal was to make comparisons that
could be used to design a larger multi-center trial if our results
suggested that donor alcohol abuse could be associated with
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a clinically meaningful difference in the incidence of PGD.
In this context, we planned from the outset to present the
descriptive results of this pilot study. Speciﬁcally, we report the
number and percentage of subjects in each category. In
addition, we calculated the odds ratio of developing PGD when
receiving an allograft from a donor with alcohol abuse versus
receiving an allograft from a donor without alcohol abuse using
logistic regression and using a generalized linear mixed model
methodology to account for multiple measurements per patient
over time. Covariate adjusted odds ratios were estimated by
a series of 2-variable models (ie, alcohol status and one of the
potentially confounding covariates). Lung transplant donor and
recipient demographic and clinical characteristics other than
PGD outcomes were examined for their relationship to donor
alcohol abuse status (donor and recipient age: Wilcoxon rank
sum test; all categorical variables: Fisher’s exact test; ICU and
hospital LOS: log-rank test). All tests were 2-sided. All analy-
ses were completed using SAS v9 for Windows 7 Enterprise
(SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics
The most common indication for transplant was chronic
obstructive pulmonary disease (COPD) (50% of all transplants)
followed by idiopathic pulmonary ﬁbrosis (41%). Sixty-ﬁve of
74 of all transplants (88%) included in the analyses were
bilateral lung transplants. The median age of these donors was
30.5 (range, 12–62) years. The most common cause of death
among donors was traumatic head injury (47.0%).
Donor and Recipient Demographics by Donor
Alcohol Use Category
Fourteen of the recipients (19%) received a lung from
a donor with heavy alcohol use (Table 1). The 2 donor alcohol
use groups were similar for age, racial distribution and smoking
history. The heavy alcohol use group had somewhat more
deaths because of traumatic injury (64% versus 43%; P 5
0.23) and a higher proportion of males (93% versus 47%;
P 5 0.002). Recipients in the 2 groups were similar for age,
racial distribution, indication for transplant, transplant type, use
of cardiopulmonary bypass, racial mismatch (African American
to Caucasian) and ischemia time. Recipients of lungs from
heavy drinkers were more likely to be male (93% versus
50%; P 5 0.005). A gender mismatch (female to male) was
somewhat less likely in the heavy alcohol use group 7% versus
20%, although this difference was not statistically signiﬁcant.
Median LOS in the ICU and in the hospital was 2 days longer in
the heavy alcohol use group.
Development of PGD
Using the consensus ISHLT deﬁnitions, PGD grades of
0, 1, 2 and 3 at 48 hours (T48) after lung transplantation
occurred in 43%, 27%, 14% and 17% of recipients,
respectively.
A little over a quarter of recipients in both groups had
grade 3 PGD on at least 1 day during the 1st 4 days post-
transplant (Table 2). However, PGD was more persistent among
recipients of lungs from heavy alcohol users, with 50% of these
PGD cases lasting 4 days (compared with 13% in the light
alcohol group). Additionally, their PGD was more likely to
occur on consecutive days. However, these differences between
the 2 groups are based on a small number of cases with grade 3
PGD. On each of the 1st 4 post-transplant days, the incidence of
grade 3 PGD was higher in the heavy alcohol use group
(Table 3). The greatest difference between the light and heavy
groups was apparent on the 1st 2 days (light versus heavy: 18%
versus 29% at 6–24 hours; 13% versus 29% at 25–48 hours),
with small differences thereafter (15% versus 21% at 49–72
hours; 8% versus 14% at 73–96 hours). On the 1st 2 days, there
also was a substantial difference in the incidence of grade 2
PGD (17% versus 0% on both days).
Odds Ratio of Developing PGD in Allograft From
Alcoholic Versus Non-Alcoholic Donors
Using a method that takes into account the multiple days
of grade 3 PGD measurement on each person, we compared the
2 groups for their odds of developing grade 3 PGD. Without
controlling for any potential confounders, the odds ratio was
1.8, with a 95% conﬁdence that the true value falls in the
interval 0.6 and 5.6. Controlling either for the donor factors of
age, traumatic brain injury (TBI) and smoking or for the
recipient factors of diagnosis, race mismatch, gender mismatch,
cardiopulmonary bypass (CPB) and type of transplant (bilateral
or not) had minimal effect on the odds ratio (range 1.7–1.9). On
average, the rate of PGD 3 per day was 22% in the heavy
alcohol use group compared with 14% in the lighter use group.
DISCUSSION
We found that 1/5 of the lung donors at our center in this
study had heavy alcohol intake when classiﬁed by validated
instruments, such as AUDIT. In addition, while the risk of
developing grade 3 PGD at least once in the 1st days post-
transplantation seemed similar between the 2 groups, the
number and duration of episodes of PGD 3 also seem greater
when the allograft came from a donor with heavy alcohol use.
For example, as disclosed in Table 2, PGD 3 lasting 4 days was
present in 2/4 versus 2/15 of recipients who experienced any
PGD 3. In parallel, we observed somewhat longer ICU and
hospital LOSs if the donor had an AUDIT $8, and the recip-
ients of allografts from donors with alcohol abuse had more
grade 3 PGD at 48 hours post-transplantation. These ﬁndings
build on previous observations that lung allograft recipients
with grade 3 PGD within the 1st 48 hours following transplant
had signiﬁcantly decreased long-term survival, as well as longer
ICU and hospital stays, when compared with recipients who
had grade 1 or 2 PGD.25
Taken together, our ﬁndings in this pilot study are
consistent with the multi-center studies showing that alcohol
abuse increases the risk of developing ARDS approximately 4-
fold in critically ill individuals and raise concern that donor
alcohol abuse could signiﬁcantly increase the risk of PGD
following lung transplantation. Our preliminary ﬁndings in this
single-center pilot study are provocative because they suggest
that donor alcohol abuse may have an adverse effect on
outcome following transplantation that cannot be predicted by
our current risk-stratiﬁcation criteria. Therefore, we believe that
it is imperative for the lung transplant community to perform
a larger multi-center study to either validate or refute an
association between donor alcohol abuse and PGD because
either result will be valuable as we work to improve outcomes
following lung transplantation.
Our ﬁndings are consistent with a growing body of
experimental and clinical evidence that excessive alcohol use
renders the lung susceptible to injury. The initial link between
alcohol abuse and ARDS was identiﬁed in a retrospective
analysis of a clinical database of 351 subjects admitted to an
ICU with an acute illness that placed them at risk for ARDS.11
This association was later conﬁrmed in a prospective, multi-
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center study of 220 patients admitted with severe sepsis.12 In the
initial study, the relative risk was approximately 2:1. However,
in the latter study in which a validated case deﬁnition of an
alcohol use disorder was used, the relative risk of ARDS in
alcoholic individuals was approximately 3.7:1. Therefore, it is
reasonable to be concerned that there is an increased relative
risk of PGD following transplantation of lung allografts from
donors with signiﬁcant alcohol abuse and that a larger multi-
center study would conﬁrm our preliminary ﬁndings in this
pilot study. In fact, even if we had determined in this pilot study
that donor alcohol abuse signiﬁcantly increased the relative risk
of PGD at the P , 0.05 level, we would still need to conﬁrm
this ﬁnding in a larger multicenter study to ensure that the
association was indeed generalizable.
To our knowledge, the AUDIT questionnaire has not
been used in other clinical studies of lung donors, particularly to
assess whether their antemortem alcohol use was associated
with poorer post-transplant outcomes in lung allograft recipi-
ents. Although the standardized United Network for Organ
Sharing questionnaires given to the surrogates of all potential
organ donors include questions about alcohol use, those
questions do not allow for speciﬁc and accurate classiﬁcation
of alcohol use disorders. Our group and others have used the
AUDIT questionnaire in similar studies of critically ill individ-
uals that have identiﬁed the increased risk of ALI in patients
with alcohol use disorders.12 Importantly, in many cases we
have relied on surrogates to answer the AUDIT questionnaires
for their loved ones, and this use of surrogates has been inde-
pendently validated by other investigators.26 Therefore,
although the use of the AUDIT questionnaire in the particular
context of lung transplantation is unique, its validated use in
other clinical studies of critical illness and ALI support its use
in this and future clinical studies of PGD and other post-
transplant outcomes.
The main limitation of our pilot study was that it was
a single-center study with a small number of alcoholic donors
TABLE 1. Lung transplant recipient and donor characteristics by donor alcohol status; Emory Transplant Center, February 2007
to January 2009
Donor AUDIT score
Pa
\8 ‡8
81% (n 5 60) 19% (n 5 14)
Overall n 5 74b
Donor characteristics
Donor age, median (range), years 31 (12–62) 26 (19–54) 0.73
Male donor 47% (28) 93% (13) 0.0020
Donor race 0.84
White 50% (30) 57% (8)
Black 33% (20) 36% (5)
Other 17% (10) 7% (1)
Donor smoked $1 pack-year 48% (29) 57% (8) 0.77
Donor traumatic brain injury 43% (26) 64% (9) 0.23
Recipient characteristics
Recipient age, median (range), years 60 (16–67) 60 (44–69) 0.59
Male recipient 50% (30) 93% (13) 0.0052
Recipient race 0.73
White 77% (46) 71% (10)
Black 22% (13) 29% (4)
Other 2% (1) 0% (0)
Recipient pathology 1.0
COPD 50% (30) 50% (7)
IPF/ILD 40% (24) 43% (6)
Other 10% (6) 7% (1)
Bilateral transplant 88% (53) 86% (12) 0.68
Recipient on CP bypass 27% (16) 21% (3) 1.0
Race mismatched (black to white) 28% (17) 29% (4) 1.0
Gender mismatched (female to male) 20% (12) 7% (1) 0.44
Ischemia time, median (range), minutesc
Left lung 270 (110–403) 256 (120–420) 0.56
Right lung 274 (110–440) 260 (75–430) 0.57
LOS in ICU, median (range), days 7 (2–68) 9 (3–50) 0.46
LOS in hospital, median (range), days 17.5 (6–150) 19.5 (7–66) 0.75
a Donor and recipient age: Wilcoxon rank sum test; all categorical variables: Fisher’s exact test; ICU and hospital LOS: log-rank test.
b In 4 of 77 subjects, the AUDIT score is missing; all analyses are based on the subset with AUDIT scores.
c The ischemic time is missing on 13 of 74 subjects (11 with AUDIT ,8 and 2 with AUDIT $8).
AUDIT, Alcohol Use Disorder Identiﬁcation Test; COPD, Chronic obstructive pulmonary disease; CP, Cardiopulmonary; ICU, intensive care
unit; IPF, IPF/ILD, idiopathic pulmonary ﬁbrosis/ interstitial lung disease; LOS, length of stay.
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and a moderately small total number of subjects. Therefore, we
recognized from the outset that it was very likely that our study
would be underpowered to identify a statistically signiﬁcant
association between donor alcohol abuse and the subsequent
development of PGD. In addition, donor alcohol use was
assessed by donor surrogates. Although this could potentially
lead to greater misclassiﬁcation of alcoholics than with self-
reports, if anything one might expect surrogate questionnaires
to underestimate the true incidence of alcohol abuse by donors.
If so, then the true impact of alcohol abuse could be even
greater than estimated by our study. Furthermore, because of
the small numbers of subjects in this study, we could not
simultaneously control for multiple confounding factors related
to both donor and recipient characteristics. Finally, we pre-
sented donor alcohol effects only on PGD and length of initial
hospital stay; other outcomes, such as infections, oxidative
stress, re-hospitalizations and long-term outcomes, were not
examined.
However, if these preliminary ﬁndings are validated in
a larger multi-center study, they would have important
implications. As there are approximately 2,000 lung transplants
performed in the United States annually, donor alcohol abuse
may be responsible for a substantial number of cases of PGD
and its associated morbidity and mortality. Therefore, we
believe that this pilot study and its ﬁndings are provocative
and that the increased risk of PGD in the context of donor
alcohol abuse is consistent with extensive experimental and
clinical evidence that overwhelmingly implicates alcohol abuse
in the development of ALI in other settings.
The role of donor-derived factors in the pathogenesis of
PGD was highlighted by a report of signiﬁcant association of
PGD among shared lung, kidney and heart recipients from the
same donor.27 Despite optimization of donor and recipient
selection criteria and advances in surgical techniques, PGD
remains essentially refractory to treatment and is the primary
cause of mortality in the immediate post-transplant
period.1,2,28,29 As a result, a considerable body of research has
focused on identifying donor risk factors that are associated
with poor outcomes following transplantation. Elevated donor
pre-transplant levels of biomarkers, such as receptor for
advanced glycation end-products,5 IL-86 and vascular endothe-
lial growth factor,7 are associated with increased risk or severity
of PGD in recipients in the post-transplant period. This current
study suggests that donor alcohol abuse is a factor that may
have a greater impact on the risk of PGD than any other single
factor identiﬁed to date. Therefore, if our results are validated in
a larger, multi-center study, they could have important impli-
cations not only for lung donor screening but also for the gen-
eration of novel therapeutic interventions. Speciﬁcally, we
could capitalize on the ever-increasing knowledge of the mech-
anisms by which alcohol abuse renders the lung susceptible to
injury to design and test treatments to limit the incidence and/or
severity of PGD.
There is considerable experimental evidence that a link
between alcohol abuse and PGD is biologically plausible. For
example, in an experimental rat model of transplantation, we
determined that tracheal allografts from alcohol-fed donor rats
developed more airway obliteration following heterotopic
transplantation than tracheal allografts from control-fed rats.18
These experimental ﬁndings argue that alcohol use, indepen-
dently of factors such as smoking or other illicit drug use ren-
ders the airway susceptible to damage following
transplantation. This experimental model in the context of air-
way transplantation builds on extensive earlier studies from our
group on the effects of alcohol on lung epithelial function. For
example, we determined that alveolar epithelial type II cells that
were isolated from alcohol-fed rats had decreased surfactant
production and were more susceptible to oxidant-mediated
injury.13 We also determined that alcohol ingestion alters alve-
olar epithelial barrier function in vivo, as reﬂected by increased
protein leak across the alveolar barrier and decreased alveolar
liquid clearance.16 A common mechanism seems to be that
alcohol ingestion dramatically decreases alveolar epithelial lev-
els of glutathione, a critical antioxidant within the alveolar
space, and increases both endotoxin-mediated acute edematous
injury in isolated lungs that were perfused ex vivo13,30 and
sepsis-mediated ALI in vivo.17 Importantly, young and other-
wise healthy subjects who meet criteria for alcohol abuse also
have profoundly decreased levels of glutathione in their
TABLE 3. Relationship between lung transplant recipient
PGD score and donor alcohol status, by period after
transplant; Emory University Hospital Lung Transplant
Service, February 2007 to January 2009
PGD score
Period n 0, % 1, % 2, % 3, %
AUDIT score
6–24 hours
,8 60 57 8 17 18
$8 14 50 21 0 29
25–48 hours
,8 60 57 13 17 13
$8 14 50 21 0 29
49–72 hours
8 60 45 25 15 15
$8 14 36 36 7 21
73–96 hours
,8 59 37 32 22 8
$8 14 36 29 21 14
AUDIT, Alcohol Use Disorder Identiﬁcation Test; PGD, primary
graft dysfunction.
TABLE 2. Grade 3 PGD by donor alcohol status; Emory
Transplant Center, February 2007 to January 2009
PGD
Donor AUDIT score
\8 ‡8
% (n/N) % (n/N)
Had grade 3 PGD on at least 1
of the 1st 4 post-transplant days
27 (16/60) 29 (4/14)
Among those who had grade 3 PGD
Length of grade 3 PGD, days
1 27 (4/15) 0 (0/4)
2 47 (7/15) 25 (1/4)
3 13 (2/15) 25 (1/4)
4 13 (2/15) 50 (2/4)
Had grade 3 PGD on
consecutive days
60 (9/15)a 100 (4/4)
a One patient in the light alcohol use group (AUDIT # 8) was
recorded with grade 3 PGD on one day but had missing PGD informa-
tion for another day and therefore cannot be categorized for this variable.
AUDIT, Alcohol Use Disorder Identiﬁcation Test; PGD, primary
graft dysfunction.
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alveolar space.14 However, although chronic glutathione
replacement in the alcohol diet in experimental animal models
prevents glutathione depletion and thereby maintains alveolar
epithelial function,13,16,17,30,31 it is unlikely that glutathione
replacement alone could rescue the alcoholic lung in the context
of ALI. For 1 reason, we determined that N-acetylcysteine, the
only approved glutathione precursor available for human use,
does not maintain the critical mitochondrial glutathione pool
during alcohol feeding and does not preserve surfactant pro-
duction.31 This is consistent with previous clinical trials in
which N-acetylcysteine therapy was minimally efﬁcacious in
patients with established ARDS, although those trials were
not directed toward patients with a history of alcohol abuse.32,33
In addition, the glutathione depletion within the airway is just 1
marker of the chronic oxidative damage that prolonged alcohol
abuse inﬂicts on the airway, and this damage cannot be imme-
diately reversed simply by the acute administration of glutathi-
one supplements. Taken together, our experimental and clinical
studies have identiﬁed that alcohol abuse causes previously
unrecognized oxidative stress and epithelial dysfunction within
the lung but that clinically signiﬁcant therapeutic interventions
will require a more comprehensive strategy than simple gluta-
thione replacement.
CONCLUSIONS
Our data suggest that donor alcohol abuse may increase
the risk of PGD following lung transplantation. Although this is
at present a preliminary ﬁnding from a relatively small single-
center study, it is consistent with the clearly established link
between alcohol abuse and ARDS and is supported by a large
body of experimental evidence over the past 2 decades showing
that alcohol renders the lung susceptible to acute edematous
injury. The results from this pilot study therefore provide
a compelling argument to design and conduct a multi-center
study to determine whether there is a true association between
donor alcohol abuse and PGD and the magnitude of such an
association if it exists. Based on the experimental and clinical
evidence linking alcohol abuse to ARDS and ALI, there is in
fact every reason to believe that PGD, which is essentially ALI/
ARDS in the context of lung transplantation, is associated with
donor alcohol abuse. The conﬁrmation (or refutation) of such an
association is critical to the lung transplant community and
would have important implications for the evaluation and risk-
stratiﬁcation of donor-recipient pairs. Perhaps even more
importantly, it would provide novel insights into the mecha-
nisms that predispose a lung allograft recipient to develop PGD
and therefore could lead to the design and testing of novel
therapies to decrease the impact of this dreaded complication.
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